Isoflavonoids from Brazilian red propolis down-regulate the expression of cancer-related target proteins: A pharmacogenomic analysis.
Isoflavonoids from Brazilian red propolis down-regulate the expression of cancer-related target proteins: A pharmacogenomic analysis.
复制标题
巴西红蜂胶中的异黄酮类化合物下调癌症相关靶蛋白的表达:药物基因组学分析。
DOI:
10.1002/ptr.6016
复制
发表时间:
2018
期刊:
影响因子:
--
通讯作者:
Rosalen,PedroLuiz
中科院分区:
文献类型:
--
作者:
Nani,BrunoDias;Franchin,Marcelo;Lazarini,JosyGoldoni;Freires,IrlanAlmeida;daCunha,MarcosGuilherme;Bueno-Silva,Bruno;deAlencar,SeverinoMatias;Murata,RamiroMendonça;Rosalen,PedroLuiz
Vestitol and neovestitol are bioactive isoflavonoids isolated from Brazilian red propolis, a uniqueApis meliferatype of propolis botanically originated fromDalbergia ecastophyllum. Although these molecules have relevant biological effects, including anticancer and immunomodulatory activities, their mechanism(s) of action and the affected pathways remain largely unknown. Here, we carried out a pharmacogenomic analysis to investigate the effects of vestitol and neovestitol on the whole‐genome expression in human tumor cells, particularly cancer‐related target proteins. HeLa cells were exposed to the compounds at IC20and genomic information of treated cells was analyzed using the Illumina transcriptome system and GeneGo MetaCore software. Our results showed that vestitol (IC20= 214.7 μM) reduced the expression of genes enrolled with the alpha tubulin (fold −3.7), tubulin in microtubules (fold −3.7), and histone h3 (fold = −3.03), and that treatment with neovestitol (IC20= 102.91 μM) downregulated prostaglandin E synthase gene (fold = −3.12), which are considered ideal targets for anticancer therapy. These data open avenues for the study of vestitol and neovestitol as potential promising candidates for anticancer therapy. Toxicological, non‐clinical, and clinical validation of the findings presented herein is needed.